

4 August 2026

Careteq establishes Advisory Board to accelerate HMR Referrals growth and AI strategy

Ms Fiona Rhody-Nicoll appointed as inaugural Chair

Careteq Limited (ASX: CTQ) ("Careteq" or "the Company"), a clinical healthtech company delivering innovative and AI-enabled healthcare solutions, is pleased to announce the establishment of an Advisory Board to support the Company's next phase of growth in its Home Medicines Review Referrals business (HMR Referrals).

The Company is also pleased to announce the appointment of Ms Fiona Rhody-Nicoll LLB (Hons) as the inaugural Chair of the Advisory Board.

Purpose of the Advisory Board

The Advisory Board has been established to provide the Careteq Board of Directors with independent, subject-matter expertise to support the Company's growth aspirations for HMR Referrals complemented by acquisition opportunities in the sector.

Consistent with the strategic priorities, the Advisory Board's remit will focus on:

- **Growth and commercial expansion** of the HMR Referrals platform, including clinic activation, pharmacist network expansion, and conversion of the Company's partnership pipeline;
- **Vertical and horizontal expansion opportunities** on the existing marketplace infrastructure;
- **AI strategy and implementation**, including advising on the Company's phased AI capability build across low-risk administrative AI, drafting AI and, subject to appropriate clinical-governance and Software as a Medical Device (SaMD) classification gating, decision-support AI;
- **Identification and evaluation of strategic opportunities**, including complementary AI capability acquisitions, technology partnerships and other inorganic opportunities aligned with the Company's growth strategy;
- **Clinical, regulatory and sector engagement**, drawing on Advisory Board members' networks across primary care, community pharmacy, aged/home care and health-tech ecosystems.

The Advisory Board is an advisory body and does not have Board-level decision-making authority. All material strategic, capital and commercial decisions remain with the Careteq Board of Directors, consistent with the Company's Delegations of Authority framework.

Summary of Advisory Board Charter

The key features of the Advisory Board Charter, as approved by the Careteq Board, include:

- **Composition** — a minimum of three and a maximum of five members, with the Chair appointed by the Careteq Board;
- **Meeting cadence** — quarterly, with additional meetings convened as required;
- **Reporting** — the Advisory Board Chair reports to the Executive Chairman of Careteq, with a written summary of each meeting provided to the Careteq Board;
- **Term** — members are appointed for an initial term of two years, renewable by mutual agreement;
- **Governance** — the Advisory Board operates within Careteq's Group governance framework, including the Continuous Disclosure Policy, Securities Trading Policy, Anti-Bribery and Corruption Policy and Code of Conduct;
- **Confidentiality** — members are bound by confidentiality obligations consistent with those applicable to Careteq's directors and officers.

Chair appointment — Ms Fiona Rhody-Nicoll LLB (Hons)

Ms Rhody-Nicoll is an executive leader with almost 20 years' experience spanning healthcare, aged care, strategic partnerships, business growth, stakeholder engagement and organisational leadership.

Ms Rhody-Nicoll previously served as Chief Executive Officer of Ward Medication Management, where she led the business's growth into Australia's leading provider of medication analysis services for aged care.

Ms Rhody-Nicoll has a strong interest in the use of technology and innovation to improve healthcare delivery, increase access to services and enhance health and quality-of-life outcomes. She brings extensive sector knowledge, commercial acumen and a deep understanding of the medication review industry, including HMR Referrals and the broader opportunities available to Careteq within the healthcare sector. Ms Rhody-Nicoll holds a Bachelor of Laws (Honours) from the University of Sheffield.

Careteq Executive Chairman Mark Simari said:

"The establishment of the Advisory Board is a natural next step following the Board's strategic decision to concentrate the Company's capital, management attention and clinical governance bandwidth on HMR Referrals. The Advisory Board will provide the Board with an independent, expert perspective on the execution of our growth and AI strategy, and on the evaluation of complementary opportunities as they emerge.

Fiona brings a rare combination of deep sector experience in medication management, executive leadership of an ASX-relevant health-tech business and a strong appreciation for how technology and artificial intelligence can reshape healthcare delivery. She is an outstanding inaugural Chair for the Advisory Board, and I look forward to working closely with her as we build out the group's membership."

Further Advisory Board appointments

The Company is progressing the appointment of additional Advisory Board members with complementary expertise across artificial intelligence, and healthcare technology. Further appointments will be announced in due course in accordance with the Company's continuous disclosure obligations.

This ASX announcement has been authorised by the Board of Careteq Limited (ASX: CTQ)

For further information, please contact:**Careteq Limited (ASX: CTQ)**

Mark Simari
Executive Chairman
P: +61 3 8866 5594
E: info@careteq.com.au

About Careteq Limited (ASX: CTQ)

Careteq Limited (ASX: CTQ) is an Australian healthtech company delivering innovative and AI-enabled solutions for the healthcare sector. The Company is dedicated to improving healthcare outcomes through its fully owned marketplace platform, HMR Referrals which streamlines the process of completing Home Medicines Reviews (HMRs).

To learn more, please visit: www.careteq.com.au/

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on Careteq's beliefs, assumptions, and expectations and on information currently available to Careteq. All statements that address operating performance, events or developments that Careteq or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Careteq or the market it operates in.

Careteq believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Careteq does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of Careteq or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For more information

Follow us on [LinkedIn](#)

To learn more about Careteq please click here: <https://www.careteq.com.au/investors-centre/>